Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Biotech-bay symbols : SNYNF save search
Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases
Published: 2024-01-29 (Crawled : 15:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
il-10 treatment collaboration sanofi
Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe Disease
Published: 2023-12-11 (Crawled : 00:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.5%
H: 1.67%
C: 0.1%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 2.15%
H: 0.0%
C: 0.0%
mze001 disease license collaboration therapeutics potential agreement therapy sanofi
Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia
Published: 2023-10-24 (Crawled : 14:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: 0.0%
thn391 treatment dementia trial potential results
Nuvig Therapeutics Appoints Dr. Alan Glicklich Chief Medical Officer
Published: 2023-10-04 (Crawled : 14:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
medical therapeutics
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update
Published: 2023-08-10 (Crawled : 23:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.52%
H: 1.05%
C: 0.47%
ALXO M | $16.24 4.77% 4.56% 440K
|
Commercial Services
|
| O: 1.0%
H: 4.17%
C: 0.0%
update program financial results
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
Published: 2023-05-08 (Crawled : 23:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.59%
H: 0.0%
C: 0.0%
RVMD | $35.56 -1.93% -1.97% 1.2M
|
Health Technology
|
| O: 0.12%
H: 0.37%
C: 0.29%
BCEL P | $0.08 0.0% 160K
|
Health Technology
|
| O: 3.0%
H: 1.94%
C: 1.94%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.5%
H: 0.17%
C: -0.31%
update financial results
ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-04-28 (Crawled : 12:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.21%
H: 0.12%
C: -2.76%
TMO | News | $577.39 0.49% 0.0% 2M
|
Health Technology
|
| O: 0.06%
H: 2.92%
C: 2.13%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -2.09%
H: 0.0%
C: 0.0%
ASLN | News | $0.4863 3.69% 3.56% 1M
|
Health Technology
|
| O: -0.22%
H: 2.58%
C: -2.13%
update pharmaceuticals financial results
Therini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases
Published: 2023-04-27 (Crawled : 14:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 3.98%
H: 1.86%
C: -0.23%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -3.56%
H: 0.0%
C: 0.0%
neurodegenerative
IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days
Published: 2023-04-19 (Crawled : 13:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.19%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
IGMS | $7.95 3.25% 3.14% 690K
|
Health Technology
|
| O: 1.7%
H: 1.19%
C: -1.39%
Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
Published: 2023-04-13 (Crawled : 22:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: 0.0%
NRIX 6 d | $13.73 -2.83% -2.91% 520K
|
Health Technology
|
| O: 1.78%
H: 11.56%
C: 10.47%
update therapeutics financial results
IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Published: 2023-03-30 (Crawled : 23:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: -0.7%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: 0.0%
IGMS | $7.95 3.25% 3.14% 690K
|
Health Technology
|
| O: 1.45%
H: 1.48%
C: -2.85%
year update financial results
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
Published: 2023-03-28 (Crawled : 12:20) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.44%
H: 0.41%
C: 0.36%
cell collaboration
Neurocentria Announces Dr. Thomas Südhof to Join the Scientific Advisory Board
Published: 2023-01-13 (Crawled : 16:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.13%
H: 0.76%
C: 0.76%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
Innovent Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the NDA for Parsaclisib (PI3Kδ inhibitor) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2023-01-06 (Crawled : 09:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: -2.69%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.3%
H: 1.86%
C: 0.82%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 1.05%
H: 0.2%
C: -0.16%
treatment designation medical granted review china
Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Published: 2022-11-17 (Crawled : 13:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.26%
H: 1.16%
C: 0.73%
CTMX | $1.635 -2.68% -2.75% 280K
|
Health Technology
|
| O: 23.14%
H: 12.75%
C: 7.38%
treatment research collaboration therapeutics cancer
CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Published: 2022-11-17 (Crawled : 13:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.26%
H: 1.16%
C: 0.73%
CTMX | $1.635 -2.68% -2.75% 280K
|
Health Technology
|
| O: 23.14%
H: 12.75%
C: 7.38%
treatment research collaboration therapeutics cancer
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Published: 2022-08-24 (Crawled : 22:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -4.66%
H: 0.0%
C: -1.69%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.48%
H: 0.0%
C: 0.0%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: -0.75%
H: 3.45%
C: 2.49%
tecvayli treatment approval
Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Published: 2022-08-08 (Crawled : 22:00) - biospace.com/
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: 0.73%
H: 0.53%
C: -0.84%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
DNLI | $15.55 -3.48% -3.6% 840K
|
Health Technology
|
| O: 1.03%
H: 7.14%
C: 3.13%
therapeutics results
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
Published: 2022-08-04 (Crawled : 23:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: 0.0%
SGMO | News | $0.4911 -5.72% -6.07% 1.2M
|
Health Technology
|
| O: -0.42%
H: 0.63%
C: -0.21%
therapeutics results
San Francisco, New York Declare Local Health Emergencies Over Monkeypox
Published: 2022-07-29 (Crawled : 15:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 4.3%
H: 0.0%
C: -0.39%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.23%
H: 0.0%
C: 0.0%
monkeypox health
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.